Artiva Biotherapeutics’ (ARTV) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Artiva Biotherapeutics (NASDAQ:ARTV) in a report issued on Wednesday,Benzinga reports. HC Wainwright currently has a $20.00 price target on the stock. HC Wainwright also issued estimates for Artiva Biotherapeutics’ Q1 2025 earnings at ($0.68) EPS, Q2 2025 earnings at ($0.70) EPS, Q3 2025 earnings at ($0.73) EPS, Q4 2025 earnings at ($0.77) EPS, FY2025 earnings at ($2.89) EPS, FY2026 earnings at ($3.44) EPS and FY2027 earnings at ($4.10) EPS.

A number of other equities analysts also recently issued reports on ARTV. Needham & Company LLC reiterated a “buy” rating and set a $23.00 price target on shares of Artiva Biotherapeutics in a research report on Tuesday. Wedbush restated an “outperform” rating and set a $18.00 price target on shares of Artiva Biotherapeutics in a research report on Tuesday. Finally, Cantor Fitzgerald dropped their target price on shares of Artiva Biotherapeutics from $23.00 to $20.00 and set an “overweight” rating for the company in a report on Tuesday. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $20.40.

Artiva Biotherapeutics Trading Down 10.7 %

ARTV opened at $3.16 on Wednesday. The firm has a fifty day moving average price of $4.71 and a 200 day moving average price of $9.23. Artiva Biotherapeutics has a 1 year low of $3.15 and a 1 year high of $17.31.

Institutional Investors Weigh In On Artiva Biotherapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of ARTV. BNP Paribas Financial Markets purchased a new position in Artiva Biotherapeutics during the third quarter worth approximately $42,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Artiva Biotherapeutics during the 4th quarter valued at approximately $52,000. Wells Fargo & Company MN grew its holdings in Artiva Biotherapeutics by 64.0% during the 4th quarter. Wells Fargo & Company MN now owns 8,616 shares of the company’s stock worth $87,000 after acquiring an additional 3,361 shares in the last quarter. MetLife Investment Management LLC bought a new stake in Artiva Biotherapeutics in the third quarter valued at about $135,000. Finally, JPMorgan Chase & Co. bought a new stake in shares of Artiva Biotherapeutics in the 3rd quarter valued at approximately $166,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.